- A laminopathy is a disorder caused by mutations in genes encoding nuclear‑lamina proteins, most notably LMNA, which produces lamin A and lamin C. These proteins form a structural scaffold beneath the inner nuclear membrane, maintaining nuclear shape, organising chromatin and regulating gene expression. When lamin structure is disrupted, the nucleus becomes fragile, chromatin organisation is altered and cells experience increased mechanical stress and genomic instability. Laminopathies therefore represent a diverse group of diseases unified by defects in nuclear architecture and its downstream consequences.
- The clinical spectrum of laminopathies is remarkably broad. Some forms primarily affect muscle, leading to cardiomyopathy, conduction defects or skeletal‑muscle dystrophy. Others manifest as metabolic disorders, such as familial partial lipodystrophy, in which adipose tissue distribution is severely altered. The most dramatic laminopathy is Hutchinson–Gilford progeria syndrome, where a cryptic splice mutation in LMNA produces progerin, a truncated lamin A isoform that permanently retains its farnesyl group. Progerin accumulation causes nuclear blebbing, impaired DNA repair and accelerated cellular senescence, resulting in rapid premature ageing. Although progerin is produced at low levels in healthy individuals, its accumulation increases with age, suggesting that laminopathy mechanisms may contribute to normal ageing.
- Laminopathies also highlight the importance of nuclear–cytoskeletal connections. Proteins such as EMD (emerin) and SUN1 interact with lamin A/C to form the LINC complex, which transmits mechanical forces from the cytoskeleton to the nucleus. Mutations affecting these interactions weaken nuclear resilience, making cells more vulnerable to mechanical stress, particularly in tissues that experience constant strain such as muscle and vasculature. This explains why many laminopathies present with cardiomyopathy, muscular dystrophy or tendon abnormalities.
- At the molecular level, laminopathies disrupt multiple pathways essential for cellular homeostasis. Nuclear deformation interferes with chromatin accessibility, altering transcriptional programmes and impairing differentiation. Persistent DNA‑damage signalling activates TP53‑dependent senescence pathways, reducing regenerative capacity and promoting tissue degeneration. Defects in lamin processing, such as impaired cleavage by ZMPSTE24, further exacerbate nuclear instability and accelerate disease progression. These mechanisms collectively demonstrate how nuclear structure is intimately linked to genome maintenance, mechanotransduction and ageing.
- Research into laminopathies has advanced rapidly, driven by their relevance to both rare genetic disease and fundamental ageing biology. Therapeutic strategies include farnesyltransferase inhibitors to reduce progerin toxicity, antisense oligonucleotides to correct LMNA splicing, and gene‑editing approaches targeting mutant alleles. These interventions not only offer potential benefit for individuals with laminopathies but also provide insight into broader strategies for modulating nuclear integrity and slowing age‑related decline.
- In summary, laminopathies are disorders caused by defects in nuclear‑lamina proteins, leading to structural instability, altered gene regulation and impaired cellular resilience. Their diverse clinical manifestations—from muscular dystrophy to premature ageing—reflect the central role of the nuclear lamina in maintaining tissue function. Understanding laminopathies continues to illuminate the molecular foundations of nuclear architecture, mechanotransduction and human ageing.
